Conservative management in ureteric hydronephrosis due to deep endometriosis: Could the levonorgestrel-intrauterine device be an option?
Endometriosis can affect up to 10% of women of reproductive age, in a wide range of clinical presentations that vary from mild to severe or deep endometriosis. Deep endometriosis can affect the urinary tract in 1-5% to 15-25% cases. Even though deep endometriosis' surgeries are usually complex with higher rate of complications, conservative management is not always considered as an option because of its high failure rates. This paper describes two cases of deep endometriosis with ureteric involvement (hydronephrosis) treated conservatively with a double-pigtail stent plus a Levonorgestrel intrauterine device, after conservative surgery, who remained symptom free with no evidence of recurrence at 3 years follow-up, avoiding radical high-risk surgery. Impact statement Several treatments have been described for endometriosis. From a symptomatic perspective, conservative medical management has been proposed with a variable response. Concerning deep endometriosis (affecting the urinary or digestive tract), the definitive treatment has always been thought to be radical surgery. However, this can lead to several complications. To illustrate a possible more conservative approach this paper describes two cases of deep infiltrating endometriosis affecting the ureter, treated conservatively with a temporary pigtail ureter stent plus a Levonorgestrel intrauterine device. The management demonstrates that, in a selected population, conservative treatment solves the urinary disease avoiding the surgical complications and, what is more, improving patients' symptoms in a permanent way. Further prospective studies are needed to confirm whether the introduction of this management in clinical practice would reduce the need for surgery thereby, avoiding high-risk surgery and improving the success rate of conservative management.
a Department of Obstetrics and Gynecology , Hospital 12 de Octubre , Madrid , Spain.
Elisa
E
Simón
a Department of Obstetrics and Gynecology , Hospital 12 de Octubre , Madrid , Spain.
Álvaro
Á
Tejerizo
a Department of Obstetrics and Gynecology , Hospital 12 de Octubre , Madrid , Spain.
José Luis
JL
Muñoz
a Department of Obstetrics and Gynecology , Hospital 12 de Octubre , Madrid , Spain.
Carmen
C
Álvarez
a Department of Obstetrics and Gynecology , Hospital 12 de Octubre , Madrid , Spain.
Laura
L
Marqueta
a Department of Obstetrics and Gynecology , Hospital 12 de Octubre , Madrid , Spain.
Jesús S
JS
Jiménez
D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage; D004715:Endometriosis / Q000150:complications / Q000628:therapy*; D005260:Female; D013509:Gynecologic Surgical Procedures; D006801:Humans; D006869:Hydronephrosis / Q000209:etiology / Q000628:therapy*; D007436:Intrauterine Devices, Medicated; D016912:Levonorgestrel / Q000008:administration & dosage; D008875:Middle Aged; D015607:Stents; D014515:Ureteral Diseases / Q000209:etiology / Q000628:therapy*
D003271:Contraceptive Agents, Female; D016912:Levonorgestrel
Conservative management; deep endometriosis; levonorgestrel intrauterine device; long term improvement; pigtail stent; ureteral hydronephrosis